



January 30, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Symbol: LALPATHLAB

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 539524

Sub: Earnings Presentation on Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025

Dear Sir/ Madam,

Please find attached a copy of Company's Q3 & 9M FY26 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-Audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025, as approved by the Board of Directors in their meeting held on January 30, 2026.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above

Results Presentation

Q3 FY26



Disclaimer

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr Lal PathLabs Limited (the "Company") for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward-looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation, nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.

Table of Contents

DLPL - At a Glance	4
Q3 FY26 Performance Overview	5
Financials	7
Key Performance Highlights	8
Management Commentary	12
Corporate Overview	13
Shareholding	38
Contact Us	40

DISCLAIMER: This presentation may contain 'forward-looking' statements at places. The Company's business operations remain subject to undetermined contingencies and risks. Dr. Lal PathLabs Limited would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/ updating them publicly.

Dr. Lal PathLabs – At a Glance



75+ years of experience in the field of diagnostics



India's Leading & Trusted Diagnostics Company



131 Mn patients serviced in last 5 years



40 NABL accredited Labs; 2 CAP accredited Labs

6,607

Patient Service Centers (PSC's)

5,012

Pathology & Radiology tests; Comprehensive Test menu

298

Labs; Geographically spread-out network

10.5%

FY25 Revenue Growth

48%


ROCE
Excl. Cash & Investments

240%

Dividend for FY24-25


Credit Rating[#]
AA Stable

Q3 FY26 Performance Overview



* PAT after impact of exceptional items of Rs. 30.1 Cr.

9M FY26 Performance Overview



* PAT after impact of exceptional items of Rs. 30.1 Cr.

Financials

Particulars (Rs. Cr.)	Q3 FY26	Q3 FY25	Gr %	9M FY26	9M FY25	Gr %
Revenue	660	597	10.6%	2,060	1,859	10.8%
Material consumed	129	117		399	364	
Employee benefit Expenses	135	126		399	367	
Fees to collection centres	96	87		294	264	
Other Expenses	121	112		372	337	
EBITDA before exceptional item	179	154	16.3%	596	527	13.1%
<i>Margins</i>	27.2%	25.8%		28.9%	28.3%	
Impact of Labour Codes	30	-		30	-	
EBITDA	149	154	-3.2%	566	527	7.4%
<i>Margins</i>	22.6%	25.8%		27.5%	28.3%	
<i>Other Income</i>	24	25		77	68	
Depreciation Cost	42	36		117	106	
Finance Cost	7	5		17	17	
PBT	124	138	-10.1%	509	471	8.0%
<i>Margins</i>	18.8%	23.2%		24.7%	25.4%	
PAT	91	98	-6.8%	378	337	12.2%
<i>Margins</i>	13.9%	16.4%		18.3%	18.1%	
EPS(Basic)	5.4	5.8	-6.6%	22.4	20.0	12.2%


Financial results of the Company are best monitored on a year-to-date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in that quarter.

Key performance highlights



- **Revenue of Rs. 660 crore in Q3 FY26**, a growth of 10.6% Y-o-Y; 9M FY26 revenue of Rs. 2060 crore, an increase of 10.8% Y-o-Y
 - Mainly sample volume driven (+7.8% Y-o-Y); Led by calibrated network expansion in our core metro markets and deeper penetration in Tier 3 and Tier 4 cities/ towns.
 - Swasthfit contributed 26% in YTD FY26
- EBITDA before exceptional items increased by 16.3% Y-o-Y in Q3 FY26 and by 13.1% Y-o-Y in YTD FY26
 - Driven by sustained volume growth, network expansion and favorable mix combined with the efficient hub-and-spoke model and technology to achieve economies of scale and cost efficiencies




Operating highlights



Robust financial performance




- Growth driven primarily by increasing patient volumes and realization
- Increase in operating margin due to economies of scale and cost efficiencies



EBITDA Margin	24.3%	27.4%	28.3%
PAT Margin	12.0%	16.3%	20.0%
ROCE	24%	35%	48%

Robust financial performance (Cont'd)



1. Fixed Asset Turnover = Total Revenue / Net PP&E as per Ind AS

- Self funded growth on account of strong cash flow generation
- Attractive fixed asset turnover ratio given asset-light model
- Current net cash position and internal accruals expected to fund next phase of growth

Management Commentary



**(Hony.) Brig. Dr. Arvind Lal,
Padma Shri
Executive Chairman**



**Mr. Shankha Banerjee,
Chief Executive Officer**



**Mr. Ved Prakash Goel,
Group CFO & CEO –
International Business**

Commenting on the performance, (Hony) Brig Dr Arvind Lal, Executive Chairman said:

"Healthcare in India is undergoing a profound transformation. We are witnessing a steady rise in lifestyle-related and chronic diseases, an ageing population with evolving care needs, and a growing awareness among consumers about the importance of early detection and preventive health.

Access to high-quality diagnostics remains uneven across the country, reinforcing the relevance of organised, technology-enabled players who can deliver reliable and standardised services at scale. This is where our purpose at Dr. Lal PathLabs remains deeply aligned.

A major milestone in this direction was the launch of Sovaaka, Operating under the philosophy of 'Science Behind Wellness', Sovaaka represents a strategic pivot from traditional disease detection toward science-led disease prevention.

We continued strengthening our offerings in high-end diagnostics, including oncology, genomics, and advanced infectious disease testing"

Commenting on the performance, Mr. Shankha Banerjee, Chief Executive Officer said:

"Our Q3 FY26 results reflect sustained organic growth and operational excellence. Our focus on Medical excellence and improved patient service remain the cornerstones of this performance.

In Q3 we continued the journey of significant clinical advancement with introduction of more than 15 new tests including a few which are "First in India". These additions were across multiple portfolios, further strengthening our high-end complex testing capabilities.

We upgraded our enterprise IT infrastructure to next generation technology, rolled out a new Agentic Bot for patients at multiple touchpoints, a digital tool for clinicians in pilot mode, and enhanced patient experience at walk-in labs and home collection with faster reporting standards in DNCR this quarter. All these initiatives and more in the pipeline are aimed to enhance the patient and clinician experience with the brand.

Our recent launch of "Sovaaka", preventive wellness program model also reimagines the patient experience with diagnostics. These initiatives solidify our position not just as a laboratory service provider, but as a comprehensive, high-tech partner in our patients' long-term health journeys"

Commenting on the performance, Mr. Ved Prakash Goel, Group CFO & CEO – International Business said:

"Q3 FY26 delivered steady revenue growth and an improved business mix, reinforcing the resilience of our operating model. Our disciplined cost management and focus on execution enabled us to sustain healthy profitability, while continuing to invest in capabilities that support scalable long-term growth.

We expanded our network in underpenetrated markets through new labs and PSCs and strengthened channel partnerships to enhance reach and increase contribution from non-metro regions. Our sustained investments in digital platforms are also generating clear efficiencies and strengthening customer experience.

With a strong balance sheet, well-defined capital allocation priorities, and a technology-driven expansion strategy, we are positioned to capture a greater share of the ongoing transition from unorganized to organized diagnostics in India. We remain confident in our ability to deliver consistent, high-quality earnings and create long-term value for our shareholders.

Corporate Overview




NATIONAL REFERENCE LAB



KOLKATA REFERENCE LAB



BENGALURU REFERENCE LAB



MUMBAI REFERENCE LAB

Overview of Dr. Lal PathLabs



Established brand

Established consumer healthcare brand in diagnostic services



Pan-India integrated coverage

298 clinical labs (including National Reference Lab at Delhi and Regional Reference labs at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs)



Varied Offerings

Catalogue of 385 test panels, 3,172 pathology tests and 1,455 radiology and cardiology tests



Unique and successful operating model

Scalable model integrated through centralized IT platform allows for network expansion

Well-positioned in one of the fastest-growing segments of the Indian healthcare industry.

Our Evolution

- **1949:** Founded by Dr. Major S. K. Lal
- **1995:** Company incorporated as Dr. Lal PathLabs Private Ltd.
- **2000:** Three clinical labs receive NABL¹ accreditation
- **2001:** Received ISO 9001:2008 certification
- **2002:** Received 'International Accreditation' from CAP²

1949-2005

Foundation

Building capabilities for scale up

2005-2010

- **2005:** onwards: Investment by WestBridge Capital
- **2008:** Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited
- **2010:** National Reference Lab set up in Delhi

- Investment by TA Associates
- Clinical laboratories expansion in North region
- Growing the business in East region
- Entry into the South and West regions
- Multiple acquisitions to scale network
- Successful IPO listing in Dec 2015

Strong position in North India, building network in other geographies

2010-2015

Higher contribution from Rest of India, Commissioned state of the art Kolkata Reference Lab

2015-2020

- Higher contribution from Rest of India business & focus on bundled test program "Swasthfit"
- Successful commissioning of Regional Reference Lab at Kolkata in 2018
- Inorganic growth through acquisition of laboratories in Western & Southern India


2020 onwards

Pan India Player – Acquired Suburban, Building South Ecosystem

1. NABL: National Accreditation Board for Calibration and Testing Laboratories.

2. CAP: College of American Pathologists.

Most trusted healthcare brand in Diagnostic Services




Pillar of a Strong Brand

- Accreditations from CAP, NABL and ISO
- Centrally administered surveillance programs
- Coverage in metros, Tier 1, Tier 2 & Tier 3+ cities
- Wide reach through PSCs and PUPs
- 24x7 access including online access and home collection
- Dedicated logistics team



Collection network



LPL's scalable business model provides strategic advantage for expansion and consolidation



Digital Touchpoints across patient journey

- Patient App/Website – Order Booking, Reports, Find Nearby Center, Test Info, Expected time of report, Live order status, App Notifications
- Partner Portal – Registration, Business snapshots, Report Download, AI enabled Recommendation engine
- Home Collection Portal – Customer Order Booking, Report status
- Seamless Omni channel Experience

DIGITAL POINT OF SALE APPLICATIONS



SAMPLE COLLECTION

- Phlebo App – Scan lab number, Documentation, Order Closures for home collection
- Phlebo Kiosk – In lab application for Phlebo
- Customer Feedback/NPS Scoring

LOGISTICS



- Live tracking of samples, inter & intra city, cash collection, dynamic routing, gamification, lab shipments
- Audit



LAB PROCESSING

- Reporting & Analysis
- Instruments integrations
- Quality & Compliance
- Workflow Management



Customers

- Historical Trends
- Cumulative Reporting
- Smart Report
- RPA For Govt. Reporting
- Live Report Status/ETR
- ABDM – DLPL amongst the early adopters

REPORT ENGINE



DATA LAKE – REAL TIME ANALYTICS

MICROSERVICES BASED ARCHITECTURE


SECURED APPLICATIONS

SCALABLE INFRA – LEVERAGING POWER OF CLOUD

ABDM - All Milestones achieved, DLPL among early adopters

Ayushman Bharat Digital Mission aims to create a National Digital Health Ecosystem to bridge the existing gap amongst different stakeholders of Healthcare ecosystem through digital highways. The mission also enables interoperability and portability of health records and support innovation and research in the health sector.

The NDHM ECOSYSTEM



The program is divided into 3 milestones from Technology enablement perspective.



Integrated: M1, M2, M3

DLPL IS AMONG THE FEW EARLY ADOPTERS WHO HAVE RECEIVED ALL M1, M2 AND M3 CERTIFICATION.

The benefits of the mission are manifold and will help the entire ecosystem, from Policy Makers to Researchers, and Health Care Professionals to Patients.

Vision, Mission & Values

VISION

Be the most trusted healthcare partner, enabling healthier lives



MISSION

To be an undisputed market leader by providing accessible, affordable, timely and quality healthcare, diagnostics, applying insights and cutting-edge technology to create value for all stakeholders




VALUES

Customer First
Ethics & Integrity
Quality
Accountability
Empathy & Compassion



DLPL Strategy for future growth



Leveraging digital infrastructure to make life easier for patients



New Website Launch

- New age user intuitive website.
- Responsive , mobile friendly web designs.
- SEO friendly for improved customer reach
- Strategic placement of Buttons and Web forms to generate more leads and better order conversion rates from website



Reco.ai

- LPL's own AI based Recommendation Engine
- Recommends Patient relevant tests as per his current health condition, past report trends, demographic details, etc.



Logistics App

- Machine Learning based FE Route Generation
- Machine Learning based Tube Scanning Bag creation process.
- Secure QR Code based handshake for every process.
- Geo-fencing and Precious sample recognition Intra and Intercity sample movement.



Wallet

- Senior Citizen Wallet: Wallet points on every booking for Senior Citizen Patients.
- Phlebo Wallet: Wallet points on enhanced superior services to customers.



One Registration


- One unified platform for all POS registrations
- Error Proofing



Chatbot 2.0

- New version of Chatbot.
- Book an appointment functionality.
- ETR and Report visibility of customer orders.
- Recommendation of Preventive Health Checkups

Genevolve: Genetic Testing Division




First in South Asia - Amyloid Typing

Amyloid Protein Typing Facility



Dr. Lal PathLabs becomes south Asia's first diagnostic chain to offer advance test for amyloidosis: a rare, life-threatening protein disorder

In a significant medical advancement, Dr. Lal PathLabs has launched South Asia's first advanced test for amyloidosis, a rare protein disorder. The test, guided by the National Amyloidosis Centre, uses cutting-edge technology to determine amyloid subtypes, enabling precise and targeted treatment.



Under the Guidance of the National Amyloidosis Centre, London (UK)

Highest Quality Standards in the Industry

Best in the Industry CAP Proficiency Testing Score at 98.0% for National Reference Lab

Consistently high EQAS Performance Testing Score at 98.3% for Satellite Labs


CAP accreditation 2 labs, NABL accreditation 40 Labs

Real time quality control monitoring

Risk based quality assurance framework

100+ Quality improvement meetings on a daily basis with the network partners

Digitally enabled solutions implemented for quality audits and trainings




Patent has been granted to Dr. Lal PathLabs for an invention related to **REAL TIME QUALITY CONTROL MONITORING** for the period of 20 years


Quality Control



Laboratory excellence



Capability building



Control Tower Implementation

“Control Tower” implementation provides a complete visibility of Patient samples across the sample processing lifecycle. The insights will help the business users to reduce delay and improve processing leading to better customer service.

Control Tower Teams

Front Desk

Failure Indicator Areas - Home Collection, Credit management & Sample/Registration Deficiency



Logistics

Failure Indicator Areas - Unregistered Samples, Bagging & Shipping of samples



Lab Operations

Failure Indicator Areas - samples scan-in & scan-out , Shipment creation, Report Validation



Digital

Failure Indicator Areas: Delay in report upload and payment



Key Highlights

- Centralized Monitoring Team for “Control Tower” Operation
- Real-time information for the delays happening across sample processing lifecycle with actionable insights
- Quick decision making
- Drill-down level information available till last leaf i.e. Lab Number / Field Executive
- Information accessible based on Roles & Rights
- Overall design is based on “Mobile First” Approach

D365 Cloud Data Lake

- Future ready Cloud architecture with easily scalable and upgradable
- Cloud ERP Microsoft Dynamics 365 for Finance & Operations
- Data for “Control Tower” is processed through “Data Lake” hosted on Cloud
- “Data Lake” helps in consolidating the data from multiple source systems and provides easy access information securely

Enhanced Customer Experience in Home Collection



Key ESG Initiatives



Commissioned 3.18 MW Solar System for generating the green energy

Use of Electric bikes for sample collection

Saved 16,43,858 Kg of CO2 emissions by using Solar power

Use of biodegradable bags for sample collection


Installed R32 refrigerant operated Inverter AC for Conserving ozone layer

All labs are equipped with Effluent Treatment Plant for wastewater treatment

49,384 hours of training for employee development

Descaling of DG Sets radiator to improve the smoke quality

Cyber Security Capability



Experienced Management team

(Hon.) Brig.
Dr. Arvind Lal
Padma Shri

Executive
Chairman



Dr. Vandana Lal

Whole-time
Director



Shankha
Banerjee

Chief Executive
Officer



Ved Prakash
Goel

Group CFO &
CEO –
International
Business



Munender
Soperna

Group Chief
Information &
Digital
Officer



Jai Prakash
Meena

Chief
Operating
Officer



Manoj Garg


Group Chief
Human
Resources
Officer



Investment Highlights



Investment Highlights



Indian Healthcare Services is a large and growing opportunity

~1.51 bn

India's expected population in 2030¹

2.5%

Government Expenditure on healthcare (as % of GDP) in FY25⁵

INR 16.5-17.5 trillion

Expected India's healthcare industry size in FY28²

~50.6%

Out of pocket expenses to overall healthcare spends³


~INR 1,000 billion

Allocated to the Ministry of Health & Family Welfare, under Union Budget 2025-26⁶

INR 42 billion


Allocated for Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) for FY2025-26⁶

Healthcare expenditure as % of GDP (2021)⁴




Source: (1) UN Department of Economic and Social Affairs, World Population Prospects 2020, CRISIL MI&A, (2) Industry, CRISIL MI&A (3) Global Health Expenditure Database accessed in March 2023, CRISIL MI&A (4) Global Health Expenditure Database accessed in May 2024, World Health Organization; CRISIL MI&A (5) Article by Outlook India, (6) Ministry of Health & Family Welfare


Transforming Indian Healthcare Landscape through Diagnostics




Growth driven by rising burden of NCDs, aging population, and heightened post-pandemic health awareness



Increased coverage shifts payment risk from the patient, driving higher utilization of essential and preventive diagnostic services




Higher shift to organised firms facilitates quality diagnostics at affordable prices



Tapping into a massive, underserved population base in Tier 2 & below cities

Drivers of India diagnostic services market


Diagnostic Services Industry Size



Screening, early detection, and monitoring reduce downstream costs

Growth Drivers

Demand for lifestyle diseases related services to grow




Increase in evidence-based treatments

Rapid Urbanization


Focus on preventive diseases and wellness

Diagnostic Services industry continues to remain highly fragmented



Source: Industry Data, Nuvama Institutional Equities Research Report

Shareholding as of 31st Dec, 2025



*Mutual Funds includes Alternate Investment Funds as well

Key Awards & Recognition



Outstanding Contribution Award in Healthcare from Foundation for Quality (India) in 2025



Leading CFO of the year- Healthcare sector (2024-25)



Lifetime Achievement Award



Top 100 Global Most Loved Workplace 2023



Gold Award
QCI - D. L. Shah Quality Awards - 2022



Best Brands Healthcare 2022



GAPIO Excellence in Diagnostics Award 2022



ICICI Lombard & CNBC TV18 India Risk Management Awards 2022 – Healthcare




CFO100 Roll of Honour 2022



Financial Express CFO of the year 2022



CSR Award 2022



EY Entrepreneur of The Year 2019 – Life Sciences & Healthcare



Data Quest Technology Award 2015 – Excellence in Implementation of Technology



VC Circle Healthcare Summit 2013 – Best Diagnostic Company



Computerworld Honors Laureate Program, 2012



Frost and Sullivan 4th Annual India Healthcare Excellence Award, 'Diagnostic Service Provider Company of the Year 2012'



Franchise India Excellence Award in Hall of Fame Category (2011, 2012)



Franchisor of the Year (Healthcare) - Franchise Plus Awards 2010



Padma Shri – (Hony) Brig. Dr. Arvind Lal (2009)

Contact Us

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 385 test panels, 3,172 pathology tests and 1,455 radiology and cardiology tests as on March 31, 2025.

As on March 31, 2025, DLPL's has 298 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). In FY25 & FY24, DLPL collected and processed approximately 86 million samples and 78 million samples from 28.8 million and 27.6 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited: Corporate Identification No:
L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com>



For further information please contact:

Ved Prakash Goel

Dr. Lal PathLabs Limited

Tel: +91 124 301 6500

Fax: +91 124 423 4468

E-mail: ved.goel@lalpathlabs.com

Siddharth Rangnekar / Nishid Solanki

CDR India

Tel: +91 22 66451209 / 1221

Fax: +91 22 66451213

Email: siddharth@cdr-india.com / nishid@cdr-india.com

Thank You

